A. Novák

发表

Economic evaluations of healthcare programmes and decision making

Johan L. Severens, J. Severens, Marieke E. van Velden, 2012, PharmacoEconomics.

The Aging Males' Symptoms (AMS) scale: Update and compilation of international versions

Pasi Pöllänen, Xavier Badia, X. Badia, 2003, Health and quality of life outcomes.

Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.

F. Schramel, P. Postmus, H. Smit, 2009, Lung cancer.

Andropause and quality of life: findings from patient focus groups and clinical experts.

J. Elbers, M. Brod, A. Novák, 2002, Maturitas.

Estimating the implicit value of statistical life based on public interventions implemented in The Netherlands

J. Severens, A. Ament, A. Novák, 2008, International Journal of Technology Assessment in Health Care.

CN3 PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRATIFICATION

P. Postmus, Murat Gok, A. Novák, 2006 .

The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability.

C. Loge, A Novák, C de la Loge, 2003, Contraception.

Development and Validation of an Acceptability and Satisfaction Questionnaire for a Contraceptive Vaginal Ring, NuvaRing®

C. Loge, A. Novák, L. Abetz, 2012, PharmacoEconomics.

Economic Evaluation of Ropinirole Prolonged Release for Treatment of Parkinson’s Disease in The Netherlands

J. V. Boven, M. Postma, M. Boomsma, 2014, Drugs & Aging.

Transferability of model-based economic evaluations: the case of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer in the Netherlands.

J. Severens, V. Tjan-Heijnen, M. Joore, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Pharmacoeconomic analysis shows that erlotinib is cost-saving versus docetaxel, and cost-effective versus best supportive care (BSC) in NSCLC: PD6-3-5

P. Postmus, C. Afram, Murat Gok, 2007 .

Pharmacoeconomics 2007; 25 (6): 497-509

M. Postma, J. Wilschut, A. Novák, 2018 .

Cost Effectiveness of Oseltamivir Treatment for Patients with Influenza-Like Illness Who Are at Increased Risk for Serious Complications of Influenza

M. Postma, J. Wilschut, A. Novák, 2012, PharmacoEconomics.